Wietske Kievit

8PUBLICATIONS
35CO-AUTHORS
PharmacogenomicsPhysiotherapyEconomic models and forecastingCancer therapy (excl. chemotherapy and radiation therapy)Reaction engineering (excl. nuclear reactions)
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jul 25, 2025
TDM-Based Tailored Dosing of Durvalumab in Lung Cancer Patients: A Comprehensive Population Pharmacokinetic-Pharmacoeconomic Evaluation.

Fenna de Vries, Eric J F Franssen, Arthur A J Smit

|Jul 27, 2022
Regaining adequate treatment responses in patients with psoriasis who discontinued dose reduction of adalimumab, etanercept or ustekinumab.

Lara S van der Schoot, Selma Atalay, Marisol E Otero

|Mar 02, 2021
If You Want to Perform a Cost-effectiveness Trial, First Do a Modeling Study.

Wietske Kievit, Alfons A den Broeder

|Dec 28, 2020
Two-year follow-up of a dose reduction strategy trial of biologics adalimumab, etanercept, and ustekinumab in psoriasis patients in daily practice.

S Atalay, J M P A van den Reek, J M M Groenewoud

|Nov 06, 2019
Correction to: Cost-Utility and Budget Impact Analysis for Stopping the Inappropriate Use of Proton Pump Inhibitors After Cessation of NSAID or Low‑Dose Acetylsalicylic Acid Treatment.

Sek Hung Chau, Reinier Luuk Sluiter, Jacqueline Geertruida Hugtenburg

|Sep 28, 2019
Cost-Utility and Budget Impact Analysis for Stopping the Inappropriate Use of Proton Pump Inhibitors After Cessation of NSAID or Low-Dose Acetylsalicylic Acid Treatment.

Sek Hung Chau, Reinier Luuk Sluiter, Jacqueline Geertruida Hugtenburg

Pageof 2

Frequent Collaborators

2 joint publications

Selma Atalay

2 joint publications

Juul M P A van den Reek

2 joint publications

Michel Wensing

2 joint publications

Elke M G J de Jong